Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 118.50p 115.00p 122.00p 118.50p 118.50p 118.50p 3,369 07:43:53
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -25.2 -23.4 - 124.51

Verona Pharma Share Discussion Threads

Showing 12751 to 12775 of 12775 messages
Chat Pages: 511  510  509  508  507  506  505  504  503  502  501  500  Older
New slide set added to the Verona website re Wedbush Investor event; hXXp:// It is interesting since they have put some numbers on the addressable market size in different areas of COPD treatment and their monthly value. If I am reading it correctly they are looking at a total of 3m people in the US at a list price of $970 per month. I don't know what proportion they could win if it gets to market. NDA filing planned for 2021/22. Any thoughts? And has anyone heard the audio today, I am at work so will check it out later.
Seems quite unloved here. I added to my holding today. I suspect a good result in the first quarter 2019 would see a re-rating here. That is only 6 months or so away. They are well funded until then. Perhaps I am missing something but it seems a fair risk/reward ??
AstraZeneca's COPD drug fails to beat out GSK rival hxxps://
I would if my losses were not so big
shakin not stirred
Validation cannot be fast tracked here. If investment not looked at as medium/long term , try something else.
War of attrition on the share price Same old same old for the last 5 Years. Does anybody feel if we get a painter on the BOD it could help us. Or a plumber to stop the share price going down the pan.Is their any other deluded person out their that actually looked at jaks CV and thought he would be the man to take this forward.IMO he has done less than CP And Mr Walker.Wait till the next fund raise this side of Christmas I reckon and then all see the value further diluted to smitherines. Sub 75p imo
shakin not stirred
Interims out for the 6 months to 30th June today. Pretty much as expected in terms of operational & financial information. They've made errors on the dates in some of the financial comparisons with previous periods, so they'll have to issue a correction later.
Singers have just published a new Verona research note which is accessible to those who subscribe to Research Tree Verona Pharma’s RPL554 is a differentiated respiratory programme with broad potential utility, supported by strong clinical data including synergistic effects with standard therapy. Our revised, conservative valuation scenario for Verona Pharma (which forms the basis of our 267p target price) is based solely on US direct sales of RPL554 as a nebulised maintenance treatment of COPD. We stress that this represents a conservative base case valuation to which potential label expansions and additiona .... (subscription required for complete note)
This study could answer a lot of questions: first and foremost which dose should be progressed for the Phase III studies 1.5mg or 6mg? then does it add to a LAMA/LAMA combo and then does it add to a LAMA/LABA/ICS triple therapy. This is gonna be a tough one, but the outcome will hopefully determine which dose to progress and how Verona are going to position RPL554 within the COPD market. I would be slightly surprised (but delighted) if they see a difference in FEV1 at 12 hours vs the LAMA/LABA and I would be surprised (and very delighted) if they see a difference at 12 hours vs the triple therapy, but if they did, we would be off to the races
Verona Pharma (VRP) News Out Just Now
Seems to me they are quite happy to keep going alone until they complete all trials which could be years away and will involve raising more cash. They said they had enough to get part way through phase3. However, I bought a small amount yesterday on the basis that someone like GSK might be keen to partner/takeover at a reasonable price which would realise value here. If not my stake at today's price would hopefully hold its value over the next six months.
Disappointing news this morning for GSK regarding this particular sub group of COPD patients, but I wonder if this might make them look elsewhere for a solution, RPL554 would seem to be an ideal candidate given that as well as being a bronchodilator, it also has anti-inflammatory properties:
Maybe you can be our nomad and drum up some interest. No interest and not surprising with grand incompetence reflected in the share price
shakin not stirred
Bewise looks very encouraging.Trust you have not seen the share price lately. If this is your strong buy shares performance I would hate to see your sell share price performance. Have to laugh at your unrivalled passion for such poor performance.
shakin not stirred
Guys have a look at the vrp website, a new presentation from the Jeffrey healthcare conference, lots of new information regarding timeframes, planned studies etc up to 2021, defo worth a look and very encouraging. A strong buy from me :)
Thanks GersemiSo riskier than our other mutual share Oxb?!People I spoke to in the market (mostly Investors) seriously confident about Verona science/tech
Today's IC - Verona Pharma Verona Pharma (VER) is responsible for the development and potential commercialisation of RPL-554 – a respiratory drug that has the potential to be used in the treatment of asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. RPL-554 differs from most of the products currently available as it combines bronchodilation – opening the airways – and anti-inflammation to treat severely ill patients. Sink: RPL-554 is still only in the second phase of development and therefore has the expensive phase three trial to come. Verona currently only has one drug in the clinical phase of development, meaning the future of the company is entirely dependent on the success of this drug’s clinical trials. The respiratory market is already incredibly crowded, which means commercialisation might be tough even if RPL-554 does gain approval. Revenues aren’t forecast for the foreseeable future, while losses are expected to widen until at least 2020. Swim: The company is aiming to ensure the drug’s dosage and formulation are ideal before progressing to the expensive phase three trial. The high value of respiratory medicines means this is a popular area of specialism for big pharma companies. That could make Verona Pharma a takeover target. Nasdaq listing provides another potential source of capital. Indeed, the group has filed a shelf registration statement with the US’ Security and Exchange Commission – meaning it can issue up to $200m in shares over the next three years. Verona has clinical trials and proven efficacy in three different respiratory illnesses. With just one drug and a great deal of development still to come, Verona remains a high-risk biotech company. The strong evidence that RPL-554 is both safe and effective makes Verona Pharma a potential takeover target for a pharma company with a big respiratory division. Swim. -
Thanks Timbo for attending and reporting on AGM. Did not mention the latest dilution at the AGM. No surprises there. Do not feel current BOD have it in them to get this commercialised if they hàd two lifetimes IMHO.Did they comment on why the share price was so pathetic.
shakin not stirred
Timbo, Firstly many thanks for attending the AGM and reporting back. Do you think there is any credible chance of VRP getting a licensing or partnership deal before phase 3 is done.
>>>Beanol I think I got an honest answer from them on the Ken Newman question (he is no spring chicken), but it is not surprising that the market was unsettled by the news. My largest worry is how they are going to position the drug and what sort of phase III trials will be required to support the positioning The drug undoubtedly works and it would be quite possible to design a phase III program to get it approved either as mono therapy or an add on to existing treatments for maintenance therapy. But how will it administered (as an add on) in a way that is convenient to patients and ensures good compliance and how do VRP ensure that it will find its way on to formularies and reimbursed by healthcare payers?
There is a detailed report on Verona Pharma's recent AGM which can be found in our members area here: hTTps:// To access the report, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hTTps:// Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the report (and reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hTTps://
Thanks VM Timbo. Very considerate of you. Were you convinced by the replies on Ken Newman's resignation Which has clearly had a drag effect on the SP? It's just the timing, lack of notice and no replacement in place Which jars
This year’s Verona Pharma AGM was held at 9.00 a.m. on Wednesday 2nd May 2018 at The London offices of NASDAQ, Woolgate Exchange, 25 Basinghall Street, London EC2V 5HA For investors who are unfamiliar with the company, Verona is a clinical stage Pharmaceutical company currently focused on developing just one asset, RPL554, which has a unique mechanism of action (PDE3/PDE4 inhibition). RPL554 is currently being developed for the treatment of COPD and Cystic Fibrosis. The company listed on Aim in 2006 through a reverse takeover of Isis Resources, raising around £2m at 4p/share, which valued the company at just under £6m. There have been numerous equity based fund raisings since 2006, including an IPO on Nasdaq (raising £70m) which took place just after a one for fifty share consolidation. The shares are currently priced at around 160p/share valuing the company at about £165m with cash on the balance sheet of around £80m (Dec 31st, 2017). The company broker (N+1 Singer) has a short term target price of 348p/share (last updated March 2018) and estimate cash burn of £35m during the next two years and £75m over 3 years. Links to the Company web site and other useful information are shown below: Verona Web site: Annual Report (year ending Dec 2017): Aim Admission document: There were just three ordinary shareholders present at the meeting, this prompted me to remind the Chairman, David Ebsworth (DE), that 9 am starts were generally unpopular with retail investors, who often have large distances to travel and the rail fares at that time of day were relatively expensive. He seemed slightly surprised, but said that they would take these comments into consideration when organizing the next AGM. In addition to the three shareholders there was the full Board of Directors and around eight of the usual AGM functionaries. After welcoming shareholders, DE kicked off the formal meeting with the resolutions and voting. There were no questions on the resolutions, most of which were passed with majorities in excess of 99.9%. For resolutions 2, 3 and 4 (the remuneration policy, remuneration report and re-election of the Chairman), between 5% and 6% of the votes cast were against the resolutions. The total votes cast in each case represented around 75% of the shares in issue. The CEO, Jan-Anders Karlsson (JAK) then gave an update on recent developments, using a slightly modified version of the slide set used for the recent H.C. Wainwright Global Life Sciences Conference (April 2018) The important points made by JAK, which were not covered directly by the slides were as follows: * RPL554 should be suitable for all CF patients, unlike the Vertex blockbuster, Kalydeco [Ivacaftor] which is only indicated for CF sufferers with the G551D gene mutation. * The full data from the COPD phase IIB study will be presented at the ERS in September. * The clinical data obtained thus far now supports the use of RPL554 in both rescue and maintenance in COPD patients already taking other commonly used COPD drugs alone, or in combination. * Verona’s Q1 update will be released on Tuesday May 8th. After the presentation we had a Q&A session lasting for around 20 – 30 minutes which I have summarized at the bottom of this report (note: it is a summary, not a verbatim account). When shareholders had exhausted all their questions, DE closed the meeting and I took the opportunity to have a brief chat with DE and JAK to raise a couple of additional topics that I hoped would get better responses than if I had asked in a formal setting. I began by asking whether they were closely following the current situation at Vernalis, where the company has just closed it US operations (at a huge loss) and effectively put itself up for sale (no doubt at the behest of Woodford and Invesco who between them hold >65% of the shares). I then suggested that if during the sale process Vernalis were to be split up into component parts, the Vernalis royalty rights for RPL554 may be up for sale at a fire sale price (note: Vernalis are entitled to a £5m milestone payment following first registration and 3% royalties on the first 10 years of sales for all products containing RPL554). DE and JAK acknowledged that they were following the Vernalis situation closely. I mentioned that Verona’s royalty arrangement with Vernalis also had a clause whereby Verona may have to pay the previous Verona Chairman (Clive Page) royalties on behalf of Vernalis. I opined that surely someone must have been seen a big conflict of interest during Clive’s tenure on the Board and that I was surprised that the situation was ever allowed to arise in the first place. DE and JAK did not agree or disagree with me, but their body language suggested to me that they shared my views. My final point to make before we all left was that there was little awareness of Verona among retail investors (giving all the usual reasons why it was desirable to increase retail investor awareness) and I went on to suggest the usual remedies, for example: more active PR, recorded interviews, paid for research notes and presentations to retail investors (mentioning that the ShareSoc Growth Company Seminars offered particularly good value). DE and JAK both seemed reasonably receptive to these suggestions, so I am in the process of following up on this. Q&As Q: Investors were surprised to hear about the unexpected departure of the Chief Medical Officer, Kenneth Newman, last month. You were silent about the reasons for the departure, was it due to a disagreement on strategy? A: Definitely not, Ken departed on good terms; maybe he has reached that time in life when you just want to take it easy. Q: Do you know what he is doing now? A: He is probably spending a lot more time fishing. Q: Until fairly recently you seemed to be undecided whether to progress CF or COPD as the priority indication, you now seem to have decided upon COPD, despite the possible advantages of progressing CF as the priority, are you sure this is the right decision? A: We will now progress COPD as a priority, the deciding factors were that we have dosed many more patients (circa 400) and COPD is a much bigger addressable market now we have established that it has an additive effect on existing COPD treatments. There is also the issue of finding sufficient patients who would qualify for large Phase III CF studies (many patients are already trialing other treatments from competing companies such as Vertex and Galapogos). Q: Your original positioning for nebulized RPL554 was to prioritize development for Emergency Room (ER) use following exacerbations and to use readmission rate following discharge as one of the end points (inspired by MediciNova’s discussion with FDA on a possible development pathway for their fast acting intra venous bronchodilator MN-221). You seem to have deprioritized ER use and prioritized maintenance therapy. Can you explain why? A: When we looked at it in detail, running a trial based on ER readmission rates would be too costly and complicated, the maintenance market is much larger and the clinical program would be much easier to implement. Q: Have you got enough cash to finish all the trials, or will you need more? A: we should have enough cash to complete the Phase II program and get half way through a phase III program Q: How much cash have you raised throughout the life of the company and how does this compare with the current market capitalization? A: Verona has raised around $170m and our current market cap is around $200m. Q: Is it really worth spending valuable resource in developing a dry powder inhalation (DPI) formulation, as you will most probably end up out-licensing the drug for DPI formats and a big pharma partner will almost certainly want RPL554 in their own proprietary device in combination with their own actives? A: We have not set out to develop a DPI formula for marketing; instead we are conducting a study with a simple single active powder formulation, in a capsule, using an old generic device. It is a proof of concept study, so it should not require very much resource. However, it should answer some of the questions that a large pharma partner would be asking during negotiations. The same goes for the aerosol formulation work. Q: In the last phase IIB study you failed to show a minimum effective dose and any sort of dose response for the primary outcome (peak FEV1). That may be OK for Europe, but FDA will probably require an additional phase II. Can you comment? A: Even though there was no dose response for FEV1, KOLs are increasingly advocating the use of other more clinically meaningful parameters as end points, for example, overall daily symptom score, which in the last study did show a highly significant dose response. The FDA have been known shift from entrenched positions in the past, furthermore there have been several important staff changes recently. We are due to have discussions with FDA before finalizing plans for Phase III. Q: With the benefit of hindsight (and a time machine), would you have included a lower dose in the Phase IIB study? A: It would have been good to have shown a dose response for FEV1 in the last study, but in addition to the reasons already given (see above), we have previously used a lower dose (0.4mg) in another study where we did demonstrate a significant dose response for FEV1. Q: You showed a significant difference in peak FEV1 for RPL554 vs controls in the last study, which is excellent. However, you could not show a significant difference in trough FEV1. Is this a problem and does this suggest that the therapeutic half-life is insufficient to match the twice daily dosing of the most popular COPD treatments such as Advair? A: See answer to question on dose response, i.e. symptom scores is more clinically relevant than FEV1. Q: Have you looked at licensing the product out to China? The Chinese COPD market is huge (100m patients) and there may be opportunities to use Chinese data to support or augment US and European regulatory filings. A: Jan-Anders has a trip to China already planned; he is due to leave in the next few days.
I will finish off the AGM notes later this evening, meanwhile it is well worth listening to the analyst Q&As in today's webcast, some of the questions are very similar to the ones asked at the AGM:
Chat Pages: 511  510  509  508  507  506  505  504  503  502  501  500  Older
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180924 23:33:46